
Groundbreaking Progress: New Hepatitis B Treatment Shows Promise
Precision BioSciences reports promising initial results from the ELIMINATE-B trial, targeting chronic Hepatitis B with PBGENE-HBV. PBGENE-HBV demonstrates a strong safety profile, as three initial participants exhibit no significant adverse effects. The treatment successfully reduces Hepatitis B surface antigens in two participants,